Zoledronic Acid (ZA) in Castrate Sensitive Prostate Cancer Does Not Prove To Be Advantageous

One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]

A Caution About Yesterday’s Post About Combining Treatments with Chemotherapy

My post to this blog that was written yesterday indicated that for certain men the early use of chemotherapy (docetaxil) could provide significant life extending benefits, especially for men with very advanced prostate cancer. For the purpose of clarification, in this case early use means in men who are still hormone responsive. Given that chemotherapy [...]

Early Chemotherapy for Men Who Are Still Hormone Responsive – For Some It Might Offer Extra Survival

When I was first diagnosed with metastatic prostate cancer one of the first questions that I asked my doctor was whether it made sense for me to start chemotherapy immediately. I very clearly remember him telling me that there was absolutely no evidence that starting chemotherapy at this early stage would do anything to extend [...]

A Personal Story with A Solution to An Uncommon Side Effect From Xtandi

I was lucky enough to have a consultant here in the UK who was able to get me Enzalutamide (Xyandi) on a compassionate use basis. It worked well for some six months for which I am very thankful but I suffered from an unusual, though listed, side effect. Apart from fatigue, which seems to be [...]

A Heroes Experiences with Prostate Cancer Clinical Trials

I was diagnosed with Stage 4 prostate cancer in November of 2008. After discussing the options with my family, I decided to try clinical trials instead of following the standard course of treatment. My first clinical trial combined 6 rounds of chemotherapy with the standard hormone replacement therapy (editors note – ADT). This trial was [...]

Go to Top